BioMark Diagnostics Inc.
BUX
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 27.20K | 27.50K | 28.10K | 28.00K | 29.50K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 27.20K | 27.50K | 28.10K | 28.00K | 29.50K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 27.20K | 27.50K | 28.10K | 28.00K | 29.50K |
| SG&A Expenses | 186.30K | 115.50K | 228.90K | 276.90K | 145.70K |
| Depreciation & Amortization | 158.10K | 41.80K | 42.60K | 42.20K | 74.80K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 445.80K | 238.30K | 446.60K | 452.30K | 377.30K |
| Operating Income | -418.60K | -210.80K | -418.50K | -424.30K | -347.70K |
| Income Before Tax | -294.00K | -239.20K | -401.30K | -455.50K | -290.20K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -294.00K | -239.20K | -401.30K | -455.50K | -290.20K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -294.00K | -239.20K | -401.30K | -455.50K | -290.20K |
| EBIT | -418.60K | -210.80K | -418.50K | -424.30K | -347.70K |
| EBITDA | -416.00K | -207.80K | -415.70K | -421.80K | -345.10K |
| EPS Basic | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 105.09M | 885.24M | 90.89M | 90.89M | 85.24M |
| Average Diluted Shares Outstanding | 105.09M | 885.24M | 90.89M | 90.89M | 85.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |